Freeport-McMoRan, AppLovin And A Major Healthcare Stock On CNBC's 'Final Trades'
Freeport-McMoRan, AppLovin And A Major Healthcare Stock On CNBC's 'Final Trades'
On CNBC's "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said AppLovin Corporation (NASDAQ:APP) is the number one performing large cap stock of the year so far.
On April 16, Morgan Stanley analyst Matthew Cost maintained AppLovin with an Equal-Weight rating and raised the price target from $55 to $70.
Stephanie Link of Hightower said she likes Freeport-McMoRan Inc. (NYSE:FCX) amid recovery in China.
On April 9, BofA Securities analyst Lawson Winder upgraded Freeport-McMoRan from Neutral to Buy and announced a $59 price target, while Scotiabank analyst Orest Wowkodaw maintained the stock with a Sector Outperform and raised the price target from $48 to $55.
Freeport-McMoRan is a top holding in the broader SPDR S&P Metals & Mining ETF (NYSE:XME).
Don't forget to check out our premarket coverage here
Jim Lebenthal of Cerity Partners named CVS Health Corporation (NYSE:CVS), which is set to report quarterly earnings soon.
CVS Health is scheduled to hold a conference call with analysts and investors on May 1 to discuss first quarter 2024 financial results. Analysts expect the company to report quarterly earnings at $1.71 per share, down from $2.2 per share in the year-ago period. The company is projected to post quarterly revenue of $89.21 billion, up from $80.81 billion in the year-earlier quarter.
Price Action:
- AppLovin shares rose 1.3% to close at $72.32 on Tuesday.
- Freeport-McMoRan shares fell 1.2% to settle at $49.41 on Tuesday.
- CVS Health shares rose 0.1% to close at $69.03 during Tuesday's session.
On CNBC's "Halftime Report Final Trades," Joshua Brown of Ritholtz Wealth Management said AppLovin Corporation (NASDAQ:APP) is the number one performing large cap stock of the year so far.
在CNBC的 “半場報告最終交易” 中，裏索爾茨财富管理公司的約書亞·布朗表示，AppLovin公司（納斯達克股票代碼：APP）是迄今爲止表現最好的大盤股。
On April 16, Morgan Stanley analyst Matthew Cost maintained AppLovin with an Equal-Weight rating and raised the price target from $55 to $70.
4月16日，摩根士丹利分析師馬修·科斯特維持AppLovin的同等權重評級，並將目標股價從55美元上調至70美元。
Stephanie Link of Hightower said she likes Freeport-McMoRan Inc. (NYSE:FCX) amid recovery in China.
Hightower的斯蒂芬妮·林克說，在中國復甦之際，她喜歡弗裏波特-麥克莫蘭銅金公司（紐約證券交易所代碼：FCX）。
On April 9, BofA Securities analyst Lawson Winder upgraded Freeport-McMoRan from Neutral to Buy and announced a $59 price target, while Scotiabank analyst Orest Wowkodaw maintained the stock with a Sector Outperform and raised the price target from $48 to $55.
4月9日，美銀證券分析師勞森·溫德將弗裏波特-麥克莫蘭金從中性上調至買入，並宣佈了59美元的目標股價，而豐業銀行分析師奧雷斯特·沃科道則維持該股的板塊跑贏大盤，並將目標股價從48美元上調至55美元。
Freeport-McMoRan is a top holding in the broader SPDR S&P Metals & Mining ETF (NYSE:XME).
弗裏波特-麥克莫蘭是更廣泛的SPDR標普金屬與礦業ETF（紐約證券交易所代碼：XME）中的頭號持股。
Don't forget to check out our premarket coverage here
別忘了在這裏查看我們的上市前報道
Jim Lebenthal of Cerity Partners named CVS Health Corporation (NYSE:CVS), which is set to report quarterly earnings soon.
Cerity Partners的吉姆·萊本塔爾將CVS Health Corporation（紐約證券交易所代碼：CVS）命名，該公司將很快公佈季度收益。
CVS Health is scheduled to hold a conference call with analysts and investors on May 1 to discuss first quarter 2024 financial results. Analysts expect the company to report quarterly earnings at $1.71 per share, down from $2.2 per share in the year-ago period. The company is projected to post quarterly revenue of $89.21 billion, up from $80.81 billion in the year-earlier quarter.
CVS Health計劃於5月1日與分析師和投資者舉行電話會議，討論2024年第一季度的財務業績。分析師預計，該公司公佈的季度收益爲每股1.71美元，低於去年同期的每股2.2美元。該公司預計將公佈892.1億美元的季度收入，高於去年同期的808.1億美元。
Price Action:
價格走勢：
- AppLovin shares rose 1.3% to close at $72.32 on Tuesday.
- Freeport-McMoRan shares fell 1.2% to settle at $49.41 on Tuesday.
- CVS Health shares rose 0.1% to close at $69.03 during Tuesday's session.
- 週二，AppLovin股價上漲1.3％，收於72.32美元。
- 週二，弗裏波特-麥克莫蘭銅金股價下跌1.2％，收於49.41美元。
- 在週二的交易中，CVS Health股價上漲0.1％，收於69.03美元。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧